Zacks: Evolus Inc (EOLS) Receives Consensus Recommendation of “Strong Buy” from Brokerages

Evolus Inc (NASDAQ:EOLS) has received a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus target price of $22.50 for the company, according to Zacks. Zacks has also given Evolus an industry rank of 178 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

Several research firms have commented on EOLS. Cantor Fitzgerald began coverage on shares of Evolus in a research note on Monday, March 5th. They issued an “overweight” rating and a $25.00 price target for the company. JMP Securities began coverage on shares of Evolus in a research note on Monday, March 5th. They issued an “outperform” rating and a $20.00 price target for the company. SunTrust Banks began coverage on shares of Evolus in a research note on Monday, March 5th. They issued a “buy” rating and a $24.00 price target for the company. Finally, Mizuho began coverage on shares of Evolus in a research note on Monday, March 5th. They issued a “buy” rating and a $21.00 price target for the company.

EOLS stock opened at $11.92 on Wednesday. Evolus has a 12 month low of $9.60 and a 12 month high of $12.97.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Macon Daily and is the property of of Macon Daily. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://macondaily.com/2018/04/12/zacks-evolus-inc-eols-receives-consensus-recommendation-of-strong-buy-from-brokerages-updated-updated-updated.html.

About Evolus

Evolus, Inc is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market.

Get a free copy of the Zacks research report on Evolus (EOLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply